Barclays: Maintaining the Elevance Health (ELV.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $584.00 to $621.00.
巴克莱：维持Elevance Health(ELV.US)评级，由增持调整至增持评级, 目标价由584.00美元调整至621.00美元。
Barclays: Maintaining the Elevance Health (ELV.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $584.00 to $621.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.